Human Molecular Genetics Advance Access originally published online on May 17, 2007
Human Molecular Genetics 2007 16(13):1639-1647; doi:10.1093/hmg/ddm113
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells
1 Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-465 Porto, Portugal, 2 Technische Universität München, Klinikum rechts der Isar, Institut für Allgemeine Pathologie und Pathologische Anatomie, D-81675 München, Germany and 3 Faculdade de Medicina da Universidade do Porto, 4200-465 Porto, Portugal
* To whom correspondence should be addressed at: Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Rua Dr Roberto Frias s/n, 4200-465 Porto, Portugal. Tel: +351 225570700; Fax: +351 225570799; Email: gsuriano{at}ipatimup.pt
Received March 9, 2007; Revised April 16, 2007; Accepted April 25, 2007
Gastric cancer associated E-cadherin germline missense mutations lead to significant functional consequences, in both the structural and signalling properties of the protein. In this study, we have characterized the effect of four E-cadherin germline missense mutations (T340A, A634V, P799R and V832M) in the interaction with the epidermal growth factor receptor (EGFR). We challenged the hypothesis that E-cadherin mutations perturb its ability to bind to EGFR, leading to constitutional activation of the EGFR, triggering activation of downstream effectors. We verified that missense mutations localized in the extracellular domain of the protein (T340A and A634V) exhibited reduced stability of the EGFR/E-cadherin heterodimers in contrast to germline mutations localized at the cytoplasmatic domain of the protein (P799R and V832M). We observed that cells expressing E-cadherin extracellular mutants displayed increased levels of phosphorylated EGFR upon ligand stimulation, when compared with cells expressing wild-type E-cadherin or intracellular mutants. We showed that upon treatment of E-cadherin extracellular mutant cells with the EGFR inhibitor, the increase of RhoA activation is abrogated and accompanied by decreased migratory behaviour, supporting the idea that Rho-like proteins are EGFR downstream effectors. Our results bring new insights into the understanding of the distinct in vitro behaviours observed for E-cadherin missense mutations localized in different domains of the protein. Furthermore, we demonstrate that E-cadherin-dependent EGFR activation contributes to enhanced cell motility, in a mechanism involving RhoA activation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Pinho, C. A. Reis, J. Paredes, A. M. Magalhaes, A. C. Ferreira, J. Figueiredo, W. Xiaogang, F. Carneiro, F. Gartner, and R. Seruca The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin Hum. Mol. Genet., July 15, 2009; 18(14): 2599 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Milsom, J. L. Yu, N. Mackman, J. Micallef, G. M. Anderson, A. Guha, and J. W. Rak Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis Cancer Res., December 15, 2008; 68(24): 10068 - 10076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Molli, L. Adam, and R. Kumar Therapeutic IMC-C225 Antibody Inhibits Breast Cancer Cell Invasiveness via Vav2-Dependent Activation of RhoA GTPase Clin. Cancer Res., October 1, 2008; 14(19): 6161 - 6170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bremm, A. Walch, M. Fuchs, J. Mages, J. Duyster, G. Keller, C. Hermannstadter, K.-F. Becker, S. Rauser, R. Langer, et al. Enhanced Activation of Epidermal Growth Factor Receptor Caused by Tumor-Derived E-Cadherin Mutations Cancer Res., February 1, 2008; 68(3): 707 - 714. [Abstract] [Full Text] [PDF]
|
|